This study provides an overview on the epigenetic regulation of LCN2, SLC22A17, and MMP9 in the major tumor types allowing the identification of novel DNA methylation biomarkers and potential epi-drug targets of TME involved in tumor progression and drug resistance. This evidence concerns the gene SLC22A17 and neoplasm.